Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-08-29
2010-02-02
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690, C424S078160, C436S901000, C436S111000, C514S018700, C514S012200, C514S002600
Reexamination Certificate
active
07655630
ABSTRACT:
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
REFERENCES:
patent: 3028395 (1962-04-01), Gillingham
patent: 3028430 (1962-04-01), Gillingham
patent: 3676492 (1972-07-01), Biel et al.
patent: 3706831 (1972-12-01), Plotnikoff et al.
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4000280 (1976-12-01), Florvall et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4064235 (1977-12-01), Yanaihara et al.
patent: 4064236 (1977-12-01), Dorn et al.
patent: 4297346 (1981-10-01), Rips et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5026827 (1991-06-01), Miyazaki et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5233025 (1993-08-01), Miyazaki et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5470997 (1995-11-01), Buechler et al.
patent: 5501987 (1996-03-01), Ordonez et al.
patent: 5529915 (1996-06-01), Phillips et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5935988 (1999-08-01), Matzke et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6235718 (2001-05-01), Balasubramanium et al.
patent: 6255285 (2001-07-01), Kotake et al.
patent: 6258836 (2001-07-01), Shashoua
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6384020 (2002-05-01), Flanner et al.
patent: 6407137 (2002-06-01), Shashoua
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6632922 (2003-10-01), Deming et al.
patent: 6680365 (2004-01-01), Deming
patent: 6686446 (2004-02-01), Deming et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao et al.
patent: 6784186 (2004-08-01), Jackson et al.
patent: 6913768 (2005-07-01), Couch et al.
patent: 7105486 (2006-09-01), Mickle et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0115725 (2002-08-01), Epstein et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2002/0173468 (2002-11-01), Lerchen et al.
patent: 2002/0183390 (2002-12-01), Javitt
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2004/0131680 (2004-07-01), Goldenheim et al.
patent: 2004/0132968 (2004-07-01), Reed et al.
patent: 2004/0204434 (2004-10-01), Shafer et al.
patent: 2005/0038121 (2005-02-01), Mickle et al.
patent: 2005/0054561 (2005-03-01), Mickle et al.
patent: 2005/0176645 (2005-08-01), Mickle et al.
patent: 0187547 (1986-07-01), None
patent: 0634999 (1995-01-01), None
patent: 1421130 (1966-03-01), None
patent: 1091089 (1967-11-01), None
patent: 1112347 (1968-05-01), None
patent: 55007242 (1980-01-01), None
patent: 55028915 (1980-02-01), None
patent: 4112858 (1992-04-01), None
patent: 7165684 (1995-06-01), None
patent: 6414901 (1964-12-01), None
patent: 6414901 (1965-07-01), None
patent: WO-9320048 (1993-10-01), None
patent: WO-9320079 (1993-10-01), None
patent: WO-9411021 (1994-05-01), None
patent: WO-9512605 (1995-05-01), None
patent: WO-9514033 (1995-05-01), None
patent: WO-9736616 (1997-10-01), None
patent: WO-9804277 (1998-02-01), None
patent: WO-9848824 (1998-11-01), None
patent: WO-9939691 (1999-08-01), None
patent: WO-9949901 (1999-10-01), None
patent: WO-0234237 (2002-05-01), None
patent: WO-03034980 (2003-05-01), None
patent: WO-2005-032474 (2005-04-01), None
patent: WO-2006121552 (2006-11-01), None
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability,”Pharmaceutical Research, 12(3): 413-420 (1995).
Amidon, G.L., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter,”Pharm Res, 16(2): 175 (1999).
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos, 21(5):165-174 (2000).
Balimane, P., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir,”Biochem Biophys Res Commun, 250(2):246-251 (1998).
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine, 340(6): 424-429 (1999).
Burnette, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition, 22(1):60-64 (1994).
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, 160(4) (2000).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics, 286(2):1166-1170 (1988).
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci, 14(1):13-19 (2001, Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther, 289(1):448-454 (1999), Abstract.
Han H., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res, 15(8):1154-1159 (1998).
Han, H.K., et al., “Ce
Bishop Barney
Krishnan Suma
Lauderback Christopher
Mickle Travis
Moncrief James Scott
Audet Maury
Darby & Darby P.C.
Shire LLC
LandOfFree
Abuse-resistant amphetamine prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abuse-resistant amphetamine prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abuse-resistant amphetamine prodrugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235177